Gerald Murphy, MD
Internal Medicine · San Francisco, CANPI 1376562462
Payments from drug & device makers
Across 252 payments — averaging $21.74 each. Meals, travel, consulting and speaking fees, gifts and royalties reported by drug and device makers.
- GSK$642
- Johnson & Johnson$631
- AstraZeneca$587
- Pfizer$568
- E.r. Squibb & Sons, L.L.C.$391
- Astellas Pharma US Inc$371
- plus $2K from 23 others
What the payments were for
- Food & beverage$5,452100%
- Education$270%
Most of this is food and beverage — typically meals provided during product presentations at a clinic or hospital. Nationally that is the single largest category of reported payments by count.
General payments by program year
Who reported the general payments
Companies are grouped under their corporate parent — a single manufacturer often files under several CMS reporting entities. Research and ownership payments are counted separately and are not in this table.
| Company | Payments | Total |
|---|---|---|
| GSK | 29 | $642 |
| Johnson & Johnson | 33 | $631 |
| AstraZeneca | 26 | $587 |
| Pfizer | 26 | $568 |
| E.r. Squibb & Sons, L.L.C. | 15 | $391 |
| Astellas Pharma US Inc | 17 | $371 |
| Novo Nordisk | 21 | $359 |
| Boehringer Ingelheim | 11 | $256 |
| Salix Pharmaceuticals, A Division Of Bausch Health US, LLC | 12 | $227 |
| Lilly USA, LLC | 7 | $190 |
| Collegium Pharmaceutical, Inc. | 7 | $154 |
| Amarin Pharma, Inc. | 7 | $152 |
| Daiichi Sankyo Inc. | 7 | $115 |
| AbbVie | 5 | $113 |
| Biogen | 4 | $106 |
| Novartis | 5 | $102 |
| Amgen | 4 | $88 |
| Radius Health, Inc. | 3 | $85 |
| Lundbeck LLC | 3 | $71 |
| Bardy Diagnostics, Inc. | 1 | $50 |
| Teva Pharmaceuticals USA, Inc. | 1 | $43 |
| Neurocrine Biosciences, Inc. | 1 | $29 |
| Sumitomo Pharma America, Inc. | 1 | $28 |
| Ironwood Pharmaceuticals, Inc | 1 | $24 |
| Ultragenyx Pharmaceutical Inc. | 1 | $24 |
| Otsuka America Pharmaceutical, Inc. | 1 | $21 |
| Exact Sciences | 1 | $19 |
| Aimmune Therapeutics, Inc. | 1 | $18 |
| Vifor Pharma, Inc. | 1 | $17 |
How this compares
$5,479 in reported general payments places this provider in the 90th percentile of 13,581 internal medicine providers in California.
Medicare billing
What this is not: this is the amount Original Medicare Part B allowed for services this provider billed in 2024. It is not their income. It excludes Medicare Advantage — now more than half of all Medicare enrollment — along with Medicaid and all commercial insurance, and it is gross practice revenue before staff, rent, supplies and malpractice premiums. CMS also suppresses any figure covering ten or fewer patients, so low-volume providers appear smaller than they are.
Most prescribed under Part D
| Drug | Claims | Cost to plans & patients |
|---|---|---|
| EliquisApixaban | 223 | $186,534 |
| Trelegy ElliptaFluticasone/Umeclidin/Vilanter | 87 | $61,486 |
| XareltoRivaroxaban | 57 | $46,069 |
| JardianceEmpagliflozin | 38 | $45,602 |
| OzempicSemaglutide | 25 | $34,232 |
| TradjentaLinagliptin | 34 | $30,195 |
| MyrbetriqMirabegron | 49 | $29,923 |
| JanuviaSitagliptin Phosphate | 33 | $24,141 |
| TrulicityDulaglutide | 15 | $19,475 |
| FarxigaDapagliflozin Propanediol | 25 | $18,324 |
| EntrestoSacubitril/Valsartan | 20 | $15,941 |
| Breo ElliptaFluticasone/Vilanterol | 28 | $11,124 |
| LinzessLinaclotide | 20 | $10,588 |
| Spiriva RespimatTiotropium Bromide | 12 | $10,325 |
| RybelsusSemaglutide | 11 | $10,314 |
Paid to pharmacies, not to this prescriber.
Companies that both paid and supply prescribed drugs
These companies both reported payments to this provider and make drugs the provider prescribed under Medicare Part D in 2024. For most specialties this overlap is expected — a cardiologist who is paid by a cardiology drugmaker also treats heart disease. It is shown so the reader can see it, not because it implies anything on its own.
| Company | Paid to this provider | Part D cost of their drugs |
|---|---|---|
| PfizerEliquis | $568 | $186,534223 claims |
| Boehringer IngelheimJardiance, Tradjenta, Spiriva Respimat | $256 | $86,12284 claims |
| GSKTrelegy Ellipta, Breo Ellipta | $642 | $72,609115 claims |
| Johnson & JohnsonXarelto | $631 | $46,06957 claims |
| Novo NordiskOzempic, Rybelsus | $359 | $44,54636 claims |
| Astellas Pharma US IncMyrbetriq | $371 | $29,92349 claims |
| Lilly USA, LLCTrulicity | $190 | $19,47515 claims |
| AstraZenecaFarxiga | $587 | $18,32425 claims |
| NovartisEntresto | $102 | $15,94120 claims |
| AbbVieLinzess | $113 | $10,58820 claims |
Reading this fairly. The Part D column is what drug plans and patients paid pharmacies — this provider received none of it, and it reflects how many patients they treat and what those drugs cost. Against peers, this provider's reported payments sit in the 90th percentile of 13,581 internal medicine providers in California.
Other internal medicine in San Francisco
- Rahul AggarwalSan Francisco$24M
- Thomas MartinSan Francisco$13.7M
- Peter HuntSan Francisco$9.8M
- Diane HavlirSan Francisco$8.4M
- Sandy WongSan Francisco$6.6M
- Nina ShahSan Francisco$5.4M
- Katy TsaiSan Francisco$3.8M
- Riley BoveSan Francisco$3.6M
- Jacob LalezariSan Francisco$3.3M
- Flavio VincentiSan Francisco$2.9M
Where these figures come from
- Payments: CMS Open Payments, program years 2019–2025 (publication P06302026_06032026).
- Billing: Medicare Physician & Other Practitioners, data year 2024. Original Medicare Part B only.
- Identity: NPPES NPI Registry, July 2026.